RT Journal Article
SR Electronic
T1 Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.25.20161869
DO 10.1101/2020.07.25.20161869
A1 Yi, Zhigang
A1 Ling, Yun
A1 Zhang, Xiaonan
A1 Chen, Jieliang
A1 Hu, Kongying
A1 Wang, Yuyan
A1 song, Wuhui
A1 Ying, Tianlei
A1 Zhang, Rong
A1 Lu, Hongzou
A1 Yuan, Zhenghong
YR 2020
UL http://medrxiv.org/content/early/2020/07/27/2020.07.25.20161869.abstract
AB Pandemic SARS-CoV-2 has infected over 10 million people and caused over 500,000 mortalities. Vaccine development is in urgent need to stop the pandemic. Despite great progresses on SARS-CoV-2 vaccine development, the efficacy of the vaccines remains to be determined. Deciphering the interactions of the viral epitopes with their elicited neutralizing antibodies in the convalescent COVID-19 population inspires the vaccine development. In this study, we devised a peptide array composed of 20-mer overlapped peptides of spike (S), membrane (M) and envelope (E) proteins, and performed a screening with 120 COVID-19 convalescent serums and 24 non-COVID-19 serums. We identified five SARS-CoV-2-specific dominant epitopes that reacted with above 40% COVID-19 convalescent serums. Epitopes in the receptor-binding domain (RBD) of S ill reacted with the convalescent serums. Of note, two peptides non-specifically interacted with most of the non-COVID-19 serums. Neutralization assay indicated that only five serums completely blocked viral infection at the dilution of 1:200. By using a peptide-compete neutralizing assay, we found that three dominant epitopes partially competed the neutralization activity of several convalescent serums, suggesting antibodies elicited by these epitopes played an important role in neutralizing viral infection. The epitopes we identified in this study may serve as vaccine candidates to elicit neutralizing antibodies in most vaccinated people or specific antigens for SARS-CoV-2 diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Science and Technology Major Project of China (2017ZX10103009), Key Emergency Project of Shanghai Science and Technology Committee (20411950103) and Development programs for COVID-19 of Shanghai Science and Technology Commission (20431900401). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of Shanghai public health clinical center, and the procedures were carried out in accordance with approved guidelines. Informed consent was obtained from the subjects. Collection of the COVID-19 convalescent serum samples was approved under the study number YJ-2020-S077-02. The serum samples of patients with symptoms of acute respiratory infections were collected under the study number YJ-2018-S045-02.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in the manuscript and supplementary files.